Skip to Main Content

Paper Details

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
Lung Cancer
57
2017
Author NameAffiliation
Luiz F L ReisSociedade Beneficiente de Senhoras Hospital Sirio Libanes
Anamaria A CamargoSociedade Beneficiente de Senhoras Hospital Sirio Libanes
  • 1 - 2

Datasets

Release 1.2